GENE NOCHTA: Open Payments
NPI 1477521326 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,392 in 45 payments from 16 companies in 2025. Trend: 2023 $862 · 2024 $1,488 · 2025 $1,392
Food & beverage: $1,392
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $229 |
| Vanda Pharmaceuticals Inc. | 7 | $187 |
| Otsuka America Pharmaceutical, Inc. | 3 | $139 |
| Paratek Pharmaceuticals, Inc. | 4 | $136 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| E.R. Squibb & Sons, L.L.C. | 1 | $115 |
| Sumitomo Pharma America, Inc. | 5 | $103 |
| Teva Pharmaceuticals USA, Inc. | 1 | $96 |
| ABBVIE INC. | 3 | $61 |
| Amgen Inc. | 2 | $38 |
Products named: FANAPT, Ozempic, REXULTI, NUZYRA, DUPIXENT, COBENFY, GEMTESA, AUSTEDO XR.
Industry payments across KY — which companies pay providers there.
